They demonstrated that the mPGES-1 inhibitor, CIII, effectively reduced PGE2 production while increasing levels of PGF2α, affecting the lipidomic and proteomic profiles in A549 lung cancer cells, and showing a decrease in cell proliferation and enhancing the effect of other drugs, such as cisplatin, combined with the inhibitor [270]. Here, PTGES is linked to lung cancer.